Non-alcoholic fatty liver disease concerns with glucokinase activators

Lancet Diabetes Endocrinol. 2018 Sep;6(9):684-685. doi: 10.1016/S2213-8587(18)30196-7.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2*
  • Double-Blind Method
  • Glucokinase
  • Humans
  • Hypoglycemic Agents
  • Non-alcoholic Fatty Liver Disease*

Substances

  • Hypoglycemic Agents
  • Glucokinase